Patrick Fabbio
Known title: Chief Financial OfficerCIK: 0001658859
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Rafael Holdings stock drops after Phase 3 trial misses goal. Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.
Transaction History
| TARA | ▼ Sell | Tax Withholding | 3,261 | $22K | 1/26/2026 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 3,063 | $17K | 1/20/2026 | View on chart |
| TARA | ▲ Buy | Grant | 28,000 | $0 | 1/16/2026 | View on chart |
| TARA | ▲ Buy | Grant | 23,500 | $0 | 1/24/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 3,061 | $15K | 1/21/2025 | View on chart |
| TARA | ▲ Buy | Grant | 22,000 | $0 | 1/19/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 27,928 | $49K | 12/21/2022 | View on chart |
| RFL | ▲ Buy | Grant | 363,103 | $0 | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment
Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.